Compare ELOX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELOX | MCHX |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Business Services |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 60.3M |
| IPO Year | 2013 | 2003 |
| Metric | ELOX | MCHX |
|---|---|---|
| Price | $13.20 | $1.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $38.25 | N/A |
| AVG Volume (30 Days) | 17.7K | ★ 26.7K |
| Earning Date | 08-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $90,291,000.00 |
| Revenue This Year | N/A | $17.69 |
| Revenue Next Year | N/A | $29.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.00 | $1.15 |
| 52 Week High | $23.40 | $2.00 |
| Indicator | ELOX | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 42.39 |
| Support Level | $10.74 | $1.20 |
| Resistance Level | $14.65 | $1.46 |
| Average True Range (ATR) | 1.28 | 0.08 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 21.89 | 25.00 |
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.